Workplace Migraine HeadAche Prevention Project (HAPPy)

Current status: recruitment closed

The Headache Prevention Project (HAPPy) Pilot is a 12-week double-blind randomised factorial trial to determine the effectiveness of low-dose blood pressure-lowering and cholesterol-lowering medications in the treatment of migraines, compared to placebo. Participants will receive a single or low-dose combination of blood-pressure lowering and/or cholesterol-lowering medications or them may receive a placebo.

Headaches are a leading cause of reduced work performance rather than absence from work. They also impact on people’s quality of life. Furthermore, migraine is the sixth highest cause of major disability worldwide. Globally, an estimated 0.8 billion people suffer from migraine.

The HAPPy trial aims to determine if these combinations of medications will reduce migraine, compared to standard therapy.

The pilot will be conducted in sites across NSW and QLD with the aim of recruiting 180 patients.

HAPPy Team Members:

Craig Anderson – Lead
Anthony Rodgers – Lead
Ruth Freed – Project Manager
Cheryl Carcel – Clinical Research Fellow
Natalie Espinosa – Senior Clinical Research Associate
Tina Cheung – Senior Project Officer
Annie Gao – Project Officer
Grace Balicki – Clinical Trials Assistant

Tension-type HeadAche Prevention Project (HAPPy Too) Pilot

HAPPy Too is an investigator-initiated, multicentre, randomised, double-blind placebo controlled study to assess the effectiveness and tolerability of low-dose combination blood pressure-lowering therapy in patients with tension-type headache (TTH).

Recurrent headache is a common, disabling condition affecting millions of Australians. TTH has a lifetime prevalence in the general population ranging between 30 and 78%. It affects approximately 1.4 billion people globally or 20.8% of the population. The study will be conducted in NSW across a number of sites with the goal of recruiting 120 patients.